[The seroprevalence of human immunodeficiency virus infection (HIV) in the Touaregs and Peuls Bororo in Niger] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[The seroprevalence of human immunodeficiency virus infection (HIV) in the Touaregs and Peuls Bororo in Niger]

Bull Soc Pathol Exot. 1995;88(3):124-5. Unique Identifier : AIDSLINE MED/96150687
Ousseini H; Meynard D; Soumana Adamou H; Faculte des Sciences de la Sante, Niamey, Niger.

Abstract: A seroepidemiological study of endemic treponematosis (bejel) in Niger allows us to realise an anonymous non correlated screening of VIH infection in Nomads: Touaregs of Tchirozerine (Agadez), Peuls Boro of Bermo (Maradi). On the 424 Touaregs screened only one was seropositive to VIH2 infection confirmed with Western blot that means 0.23% of seroprevalency comparable to that 0.50% found in the general population. The seroprevalency of trepronematosis (VDRL + TPHA+) is 7% in the range of 5 to 15 years old (80%), period which corresponds to the transmission of Bejel. Moreover this population don't travel to the seaborder countries. Concerning the 213 of the Peuls Bororo screened we had only 3 undetermined reactions to Western blot 1 and 2, despite the high seroprevalence of the treponematosis (VDRL+ TPHA+): 22% mostly in the subjects of more than 15 years old (89.36%) which is the sexual intercourse and exodus period to the seaborder countries, where 66% of our VIH patients are infected.
Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY Adolescence Adult Bejel/EPIDEMIOLOGY Child Child, Preschool English Abstract Ethnic Groups/*STATISTICS & NUMER DATA Female Human *HIV Seroprevalence HIV-2 Male Niger/EPIDEMIOLOGY Transients and Migrants/STATISTICS & NUMER DATA JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/epidemiologyadolescenceadultbejel/epidemiologychildchild,preschoolenglishabstractethnicgroups/KWDstatistics&numerdatafemalehumanKWDhivseroprevalencehiv-2maleniger/epidemiologytransientsandmigrants/statistics&numerdatajournalarticle
960530
M9651052

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .